Arena: Pfizer's bowel disease drug succeeds in late-stage study

Pfizer In. said on March 23 the company's experimental treatment for an inflammatory bowel disease, acquired during 2021 as part of a $6.7 billion deal for Arena Pharmaceuticals, succeeded in a late-stage trial.